Tisdag 17 November | 13:01:32 Europe / Stockholm
Est. tid*
2027-02-11 08:00 Bokslutskommuniké 2026
2026-11-12 - Kvartalsrapport 2026-Q3
2026-09-01 - Extra Bolagsstämma 2026
2026-08-20 - Kvartalsrapport 2026-Q2
2026-06-22 - X-dag ordinarie utdelning SPERM 0.00 SEK
2026-06-18 - Årsstämma
2026-05-07 - Kvartalsrapport 2026-Q1
2026-02-11 - Bokslutskommuniké 2025
2025-11-12 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-06-16 - Årsstämma
2025-05-09 - X-dag ordinarie utdelning SPERM 0.00 SEK
2025-05-07 - Kvartalsrapport 2025-Q1
2025-02-17 - Extra Bolagsstämma 2025
2025-02-12 - Bokslutskommuniké 2024
2024-11-28 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-05-13 - X-dag ordinarie utdelning SPERM 0.00 SEK
2024-05-10 - Årsstämma
2024-03-25 - Extra Bolagsstämma 2024
2024-02-09 - Bokslutskommuniké 2023
2023-10-13 - Kvartalsrapport 2023-Q3
2023-07-14 - Kvartalsrapport 2023-Q2
2023-05-15 - X-dag ordinarie utdelning SPERM 0.00 SEK
2023-05-12 - Årsstämma
2023-04-19 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-12-19 - Extra Bolagsstämma 2022
2022-10-14 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-13 - X-dag ordinarie utdelning SPERM 0.00 SEK
2022-05-12 - Årsstämma
2022-04-12 - Kvartalsrapport 2022-Q1
2022-02-10 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-14 - X-dag ordinarie utdelning SPERM 0.00 SEK
2021-05-12 - Årsstämma
2021-05-04 - Kvartalsrapport 2021-Q1
2021-02-12 - Bokslutskommuniké 2020
LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Spermosens är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar produkter för manlig infertilitet och individuellt anpassade fertilitetsbehandlingar. Forskning och utveckling bedrivs via en egen teknologisk plattform som analyserar spermiekvalitén som vidare används för medicinskt underlag och potentiell befruktning. Störst verksamhet återfinns inom den nordiska marknaden.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Spermosens AB (publ) to Host Live Q&A Town Hall on 19 November 2026

2026-11-16 11:46:36

Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live Q&A town hall on Thursday, 19 November 2026, at 12:00 CET. CEO Tore Duvold will address questions regarding the Company's recent announcements.

The session is organized as a dedicated Q&A to provide shareholders and other stakeholders with the opportunity to engage directly with the Company's CEO. The town hall follows the publication of the Company's Q3 2026 report and forms part of Spermosens' commitment to regular investor engagement, with Q&A sessions typically held approximately one week after the publication of each quarterly report.

Town Hall Details

  • Date: Thursday, 19 November 2026
  • Time: 12:00 CET
  • Language: English and Swedish
  • Join Town Hall meeting:

https://teams.microsoft.com/l/meetup-join/19%3ameeting_Zjk1ZDQ5OTEtOWNkNC00MTg2LWIyMzYtYmZkNTc4NWYyODVh%40thread.v2/0?context=%7b%22Tid%22%3a%227a6fe723-25f0-4904-8ffa-2bbf2e6af406%22%2c%22Oid%22%3a%2223998060-0cf4-4e02-9910-1e2cc4e0f55f%22%7d

 

Participation and Submission of Questions

The town hall is open to all interested parties. Participants are invited to submit questions in advance or during the session. The Company may consolidate similar questions to address as many topics as possible. Answers will be limited to information that has already been made public.

  • Advance Questions: Please email info@spermosens.com
  • Questions During the Session: Please use the Q&A function in Teams
  • Deadline for Advance Questions: Wednesday, 18 November 2026

 

For more information, please contact:

Tore Duvold, CEO

E-mail: info@spermosens.com

 

About Spermosens AB

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market.

The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com.